Galderma Hits Lupin With Rosacea Drug Patent Suit

Law360, New York (July 6, 2009, 12:00 AM EDT) -- Dermatology company Galderma Laboratories Inc. and New York University have accused India-based drugmaker Lupin Ltd. of infringing the patents covering Oracea, a treatment for the chronic inflammatory skin disease rosacea.

In a lawsuit filed Thursday in the U.S. District Court for the District of Delaware, NYU, Galderma and the Research Foundation of State University of New York said Lupin and its U.S.-based subsidiary Lupin Pharmaceuticals Inc. infringed their patents for Oracea by filing an abbreviated new drug application with the U.S. Food and Drug Administration....
To view the full article, register now.